20 years
Franco Parodi MD
With every breath, we find solutions. Let us take care of your lungs and improve your quality of life.
Pulmonologist
Franco Parodi MD
Pulmonologist
With every breath, we find solutions. Let us take care of your lungs and improve your quality of life.
Services
Services Provided by Dr. Parodi
Personalized treatment
Personalized treatment
Management of chronic diseases
Management of chronic diseases
Care for sleep apnea patients
Care for sleep apnea patients
About me
Franco Parodi MD
As a pulmonary and critical care physician and educator, I have been serving patients for more than 20 years. I am currently a clinical assistant professor at Michigan State University College of Osteopathic Medicine, where I teach and mentor medical students, residents and fellows. I am also the associate program director of the pulmonary and critical care medicine fellowship at Ascension Macomb-Oakland, where I oversee the curriculum, medical education, evaluation, and recruitment of fellows. In addition, I practice in the outpatient clinic where I provide comprehensive and compassionate care to patients with multiple pulmonary diseases. I am board certified in internal medicine, pulmonary diseases and critical care medicine and I have extensive expertise in pulmonary function testing (PFT), bronchoscopy, endobronchial Ultrasound (EBUS), thoracentesis, pleural catheters, etc. I have also published multiple peer-reviewed articles and presented at national and international conferences on various topics related to pulmonary and critical care medicine.
My mission is to advance the field of pulmonary diseases and critical care medicine through clinical excellence, education, and clinical research, and to contribute to the health and well-being of the community. I value teamwork, critical thinking, innovation, and lifelong learning, and I am always eager to collaborate with and learn from other professionals in the field.
Research
Explore the Innovative
Research of Dr. Parodi
Dr. Franco Parodi is dedicated to improving respiratory health through innovative clinical research in pulmonary medicine. With a focus on phases 2, 3, and 4 clinical trials, our experienced team works tirelessly to bring safe and effective treatments to patients with respiratory conditions. We are committed to serving the community, especially those with limited resources, by providing access to cutting-edge treatments and raising awareness about respiratory health. Our research interests encompass a wide range of internal medicine and pulmonary disorders,. Through our dedication to both clinical advancements and community service, we strive to enhance respiratory health and empower individuals in the Detroit Metro Area and beyond. We have ongoing trials in the areas of Asthma, COPD, Chronic Bronchitis, Pulmonary Hypertension, Interstitial Lung disease, Vaccination, etc.
Specialty/ Practice
Discover Dr. Parodi's Specialized Practice
Pulmonary Diseases
Clinical Research
Critical Care Medicine
Sleep
Health
Expertise Areas
In-Depth Lung Expertise by Dr. Parodi
Procedures
Advanced Lung Procedures by Dr. Parodi
Blog
Breathing Knowledge: Explore Dr. Parodi's Acclaimed Articles.
Article 1
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIFIED, OPEN-LABEL, ACTIVE-CONTROLLED, PARALLEL-GROUP, EFFECTIVENESS STUDY, COMPARING FF/UMEC/VI WITH NON-ELLIPTA USUAL CARE (ICS/LABA) IN ADULT PARTICIPANTS WITH UNCONTROLLED ASTHMA
Article 2
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY ASSESSING EXACERBATION RATE, ADDITIONAL MEASURES OF ASTHMA CONTROL AND SAFETY IN ADULT AND ADOLESCENT SEVERE ASTHMATIC PARTICIPANTS WITH AN EOSINOPHILIC PHENOTYPE TREATED WITH GSK3511294 COMPARED WITH MEPOLIZUMAB OR BENRALIZUMAB
Article 3
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SAR440340/REGN3500/ITEPEKIMAB (ANTI- IL-33 MAB) IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Article 4
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 52 WEEKS IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA _EXHALE-3
Article 5
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 52 WEEKS IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA_EXHALE-4
Article 6
BATURA: A Comparison of PT027 vs PT007 Used as Needed in Participants with Asthma
Article 7
Are We Diving Too Deep With Daily COVID-19 Testing? Ronny Y.Hadid MD 1, Muhammad Syed DO 2, Noah Hochstetler DO 2, Oscar F. Parodi Ortiz De Villate MD1 1 Department of Pulmonary and Critical Care Medicine, Ascension Macomb-Oakland Hospital, Warren, MI,2 Department of Internal Medicine, Ascension Macomb-Oakland Hospital, Warren, MI
Article 8
“A CASE OF ASPERGILLUS ENDOCARDITIS WITH LONG TERM DIALYSIS”: https://www.sciencedirect.com/science/article/pii/S0735109723034472 Faiza Choudhry, Sean Dawes, Sabina Custovic, George Yassa, Sailokesh Pagadala, Franco Parodi, Dustin Harmon, Ascension Macomb-Oakland Hospital, Warren, MI, USA
Article 9
TWELVE-WEEK EFFICACY AND SAFETY STUDY OF MOMETASONE FUROATE/FORMOTEROL 200/10 MICROG AND 400/10 MICROG COMBINATION TREATMENTS IN PATIENTS WITH PERSISTENT ASTHMA PREVIOUSLY RECEIVING HIGH-DOSE INHALED CORTICOSTEROIDS
Article 10
Weinstein SF, et al. Allergy Asthma Proc. 2010 Jul-Aug;31(4):280-9. doi: 10.2500/aap.2010.31.3381. Epub 2010 Aug 3. PMID: 20687982.
Article 11
EFFICACY AND TOLERABILITY OF SALMETEROL/FLUTICASONE PROPIONATE VERSUS MONTELUKAST IN CHILDHOOD ASTHMA: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY
Article 12
Maspero J, et al. Clin Ther. 2008. PMID: 18803991 Clinical Trial.
Certifications / Affiliations
Dr. Parodi's Certified Expertise and Affiliations.
FAQs
Your Lung Questions Answered
The main function of the lungs is to facilitate the exchange of oxygen and carbon dioxide between the air we breathe and our bloodstream. Oxygen is taken in during inhalation and transported to cells throughout the body, while carbon dioxide, a waste product of cellular metabolism, is removed from the bloodstream during exhalation.
Common symptoms of lung diseases include persistent coughing, shortness of breath, chest pain, wheezing, coughing up blood or mucus, fatigue, and recurring respiratory infections.
Smoking damages the lungs and significantly increases the risk of developing lung diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, and emphysema. It also worsens conditions like asthma and can lead to reduced lung function and respiratory infections.
To improve indoor air quality and protect lung health, it’s important to minimize exposure to indoor pollutants such as tobacco smoke, dust, mold, and chemicals. Proper ventilation, regular cleaning, using air purifiers, and avoiding smoking indoors are effective measures.
Medical tests used to assess lung function include spirometry, which measures how much air you can inhale and exhale and how quickly you can exhale, and imaging tests such as chest X-rays and CT scans to evaluate lung structure and detect abnormalities like tumors or lung inflammation.
contact